These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 19822073

  • 1. Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules.
    Licastro F, Chiappelli M, Ianni M, Porcellini E.
    Int J Immunopathol Pharmacol; 2009; 22(3):567-72. PubMed ID: 19822073
    [Abstract] [Full Text] [Related]

  • 2. TNF-α antagonists beyond approved indications: stories of success and prospects for the future.
    Karampetsou MP, Liossis SN, Sfikakis PP.
    QJM; 2010 Dec; 103(12):917-28. PubMed ID: 20802008
    [Abstract] [Full Text] [Related]

  • 3. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H, Horiuchi T, Tsukamoto H, Ueda N.
    Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
    [Abstract] [Full Text] [Related]

  • 4. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in rheumatoid arthritis].
    Sibilia J.
    Med Sci (Paris); 2009 Dec; 25(12):1033-8. PubMed ID: 20035675
    [Abstract] [Full Text] [Related]

  • 5. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
    Bourne T, Fossati G, Nesbitt A.
    BioDrugs; 2008 Dec; 22(5):331-7. PubMed ID: 18778114
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Tumor necrosis factor inhibitors in psoriasis: an update.
    Kerdel FA, Strober BE.
    Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S31-6. PubMed ID: 24979543
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 1. TNF inhibitors].
    Amano K.
    Nihon Naika Gakkai Zasshi; 2011 Oct 10; 100(10):2966-71. PubMed ID: 22175139
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F, Anelli MG, Rinaldi A, Serafino L, Covelli M, Scioscia C, Iannone F, Lapadula G.
    Drug Dev Res; 2014 Nov 10; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [Abstract] [Full Text] [Related]

  • 12. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
    Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, Brown D, Robinson M, Bourne T.
    Inflamm Bowel Dis; 2007 Nov 10; 13(11):1323-32. PubMed ID: 17636564
    [Abstract] [Full Text] [Related]

  • 13. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.
    Fénix-Caballero S, Alegre-del Rey EJ, Castaño-Lara R, Puigventós-Latorre F, Borrero-Rubio JM, López-Vallejo JF.
    J Clin Pharm Ther; 2013 Aug 10; 38(4):286-93. PubMed ID: 23590560
    [Abstract] [Full Text] [Related]

  • 14. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.
    Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP.
    Pharmacol Ther; 2008 Feb 10; 117(2):244-79. PubMed ID: 18155297
    [Abstract] [Full Text] [Related]

  • 15. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis.
    Palframan R, Airey M, Moore A, Vugler A, Nesbitt A.
    J Immunol Methods; 2009 Aug 31; 348(1-2):36-41. PubMed ID: 19567252
    [Abstract] [Full Text] [Related]

  • 16. Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.
    Sánchez-Cano D, Callejas-Rubio JL, Ruiz-Villaverde R, Ríos-Fernández R, Ortego-Centeno N.
    Mediators Inflamm; 2013 Aug 31; 2013():286857. PubMed ID: 23983404
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Callhoff J, Sieper J, Weiß A, Zink A, Listing J.
    Ann Rheum Dis; 2015 Jun 31; 74(6):1241-8. PubMed ID: 24718959
    [Abstract] [Full Text] [Related]

  • 18. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease.
    Chang JT, Lichtenstein GR.
    Nat Clin Pract Gastroenterol Hepatol; 2006 Apr 31; 3(4):220-8. PubMed ID: 16582964
    [Abstract] [Full Text] [Related]

  • 19. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis.
    Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M.
    PLoS One; 2012 Apr 31; 7(1):e30275. PubMed ID: 22272322
    [Abstract] [Full Text] [Related]

  • 20. anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab.
    Armuzzi A, Lionetti P, Blandizzi C, Caporali R, Chimenti S, Cimino L, Gionchetti P, Girolomoni G, Lapadula G, Marchesoni A, Marcellusi A, Mennini FS, Salvarani C, Cimaz R.
    Int J Immunopathol Pharmacol; 2014 Apr 31; 27(1 Suppl):11-32. PubMed ID: 24774504
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.